Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FKVG1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,494
Award facts
- Contract value 100% obligated
- $2,493.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $2,493.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) 30 mg/mL pens. The award was issued on January 6, 2026, with an ultimate completion date of January 7, 2026, and carries no set-aside designation. This delivery order represents a routine procurement under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract with the Defense Logistics Agency, which was awarded in November 2025 with a $499.999 billion ceiling value through December 31, 2036.
DMS Pharmaceutical Group serves as a critical regional prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy, supplying a comprehensive portfolio of pharmaceutical products and medical consumables to Department of Defense healthcare facilities globally. The company has demonstrated consistent performance across numerous delivery orders since its appointment as a prime vendor, delivering everything from specialty biologics and oncology treatments to routine medications and medical supplies. This particular delivery order for FASENRA, a biologic agent used to treat eosinophilic asthma and other conditions, exemplifies the company's role in supporting the specialized pharmaceutical requirements of military medical operations.
Quick answers
Who was awarded contract SPE2DR26FKVG1?
SPE2DR26FKVG1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FKVG1 worth?
The government has obligated $2,494 on SPE2DR26FKVG1.
Is contract SPE2DR26FKVG1 an order under another contract?
Yes. SPE2DR26FKVG1 is a delivery order under SPE2DR25D9228, an indefinite delivery contract.
Was contract SPE2DR26FKVG1 competed?
The extent of competition for SPE2DR26FKVG1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award